Emerging role of m6A modification in ovarian cancer: progression, drug resistance, and therapeutic prospects

Abstract

Ovarian Cancer (OC) ranks as a prominent contributor to mortality among female reproductive system associated cancers, particularly the prevalent subtype epithelial Ovarian Cancer (EOC). Despite advancements in treatment modalities, the prognosis for OC patients remains grim due to limitation of current therapeutic methodology such as high cytotoxicity of chemotherapeutic agents and tumor relapse making existing chemotherapy ineffective. Recognizing the limitations of a broad-spectrum approach to treating OC, a shift toward targeted therapies aligning with unique molecular features is imperative. This shift stems from an incomplete understanding of OC’s origin, distinguishing it from extensively researched malignancies such as cervical or colon cancer. At the molecular level, postsynthetic modifications—DNA, RNA, and protein—shape transcriptional, posttranscriptional, and posttranslational processes. Posttranscriptional regulatory mechanisms, including RNA modifications are termed epitranscriptomic and play critical roles in this process. For more than five decades, 100+ RNA post-synthetic modifications, notably N6-methyladenosine (m6A), most prevalent RNA modification in mammals, dynamically regulate messenger RNA (mRNA), and non-coding RNA (ncRNA) life orchestrated via writers, erasers, and readers. The disruption of m6A modifications are found in several cancers, including OC, underscores pivotal role of m6A. This review focused on m6A modifications in coding and non-coding RNAs, emphasizing their role as prognostic markers in OC and their impact on development, migration, invasion, and drug resistance. Additionally, RNA-modified regulators have been explored as potential molecular and therapeutic targets, offering an innovative approach to combatting this challenging malignancy.

Special Issue “Ovarian Cancer: Advances on Pathophysiology and Therapies”

“…Finally, Chitcholtan and colleagues evaluated the anticancer effects of resveratrol, a natural compound with several beneficial effects [22][23][24][25], on ovarian cancer cell lines, i.e., OVCAR-8 and SKOV-3, grown on the chorioallantoic membrane (CAM) of chicken embryos. The authors found that resveratrol significantly reduced angiogenic activities, pNF-κB levels, and SLUG protein levels, suggesting that this compound may have the potential to impact the behavior of ovarian cancer progression.…”